Search Results - Brecl, Constance

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia

    Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia by Gutman, Jonathan A, Winters, Amanda, Kent, Andrew, Amaya, Maria, McMahon, Christine, Smith, Clayton, Jordan, Craig T, Stevens, Brett, Minhajuddin, Mohammad, Pei, Shanshan, Schowinsky, Jeffrey, Tobin, Jennifer, O'Brien, Kelly, Falco, Angela, Taylor, Elizabeth, Brecl, Constance, Zhou, Katie, Ho, Phuong, Sohalski, Connor, Dell-Martin, Jessica, Ondracek, Olivia, Abbott, Diana, Pollyea, Daniel A

    Published in Haematologica (Roma)
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Higher-Dose Venetoclax with Measurable Residual Disease-Guided Azacitidine Discontinuation in Newly Diagnosed Patients with Acute Myeloid Leukemia: Phase 2 Hiddav Study

    Higher-Dose Venetoclax with Measurable Residual Disease-Guided Azacitidine Discontinuation in Newly Diagnosed Patients with Acute Myeloid Leukemia: Phase 2 Hiddav Study by Gutman, Jonathan A., Winters, Amanda C., Kent, Andrew, Amaya, Maria L., McMahon, Christine M., Smith, Clayton, Jordan, Craig T, Stevens, Brett M., Minhajuddin, Mohammad, Pei, Shanshan, Schowinsky, Jeffrey, Tobin, Jennifer, O'Brien, Kelly, Falco, Angela, Taylor, Elizabeth, Brecl, Constance, Ho, Phuong, Sohalski, Connor, Dell-Martin, Jessica, Ondracek, Olivia, Abbott, Diana, Pollyea, Daniel A.

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: